Use of intraoperative frontal sinus mometasone-eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polyps

Int Forum Allergy Rhinol. 2022 Nov;12(11):1330-1339. doi: 10.1002/alr.23005. Epub 2022 May 19.

Abstract

Background: Mometasone-eluting stents (MES) have demonstrated improvement in short-term endoscopic outcomes and reduce short- to medium-term rescue interventions. Their effect on the local inflammatory environment, longer-term patient-reported outcomes, and radiographic severity have not been studied.

Methods: Middle meatal mucus and validated measures of disease severity were collected before and 6 to 12 months after endoscopic surgery in 52 patients with chronic rhinosinusitis with nasal polyps (CRSwNPs). Operative findings, type 2 mediator concentrations, intraoperative variables, and disease severity measures were compared between those who did and those who did not receive intraoperative frontal MES.

Results: A total of 52 patients with CRSwNPs were studied; 33 received frontal MES and were compared with 19 who did not. Pre-endoscopic sinus surgery (ESS) middle meatus (MM) interleukin (IL) 13 and eosinophil cationic protein (ECP) were higher in the stented group (p < 0.05), but pre-ESS clinical measures of disease severity were similar as were surgical extent and post-ESS medical management. Intraoperative eosinophilic mucin was more frequent in the stented group (58% vs 11%, p = 0.001). IL-5 (p < 0.05) and IL-13 (p < 0.001) decreased post-ESS in the stented group, but this was not observed in the nonstented group. Post-ESS IL-4 and IL-13 were higher in the nonstented vs stented group (p < 0.05 for both).

Conclusion: Although patients who received intraoperative frontal MES had significantly higher pre-ESS MM IL-13 and ECP, patients who received frontal MES had lower concentrations of IL-4 and IL-13 than those who did not at a median of 8 months post-ESS. However, these changes did not correspond to significantly different measures of symptomatic or radiographic disease severity.

Keywords: CRSwNP; endotype; mometasone; nasal polyps; patient-reported outcome measures; sinus stent.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Chronic Disease
  • Drug-Eluting Stents*
  • Endoscopy
  • Frontal Sinus*
  • Humans
  • Interleukin-13
  • Interleukin-4
  • Interleukin-5
  • Mometasone Furoate / therapeutic use
  • Nasal Polyps* / surgery
  • Rhinitis* / surgery
  • Sinusitis* / surgery

Substances

  • Interleukin-5
  • Interleukin-13
  • Mometasone Furoate
  • Interleukin-4